Complement and the atypical hemolytic uremic syndrome in children
Open Access
- 1 November 2008
- journal article
- review article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 23 (11), 1957-1972
- https://doi.org/10.1007/s00467-008-0872-4
Abstract
Over the past decade, atypical hemolytic uremic syndrome (aHUS) has been demonstrated to be a disorder of the regulation of the complement alternative pathway. Among approximately 200 children with the disease, reported in the literature, 50% had mutations of the complement regulatory proteins factor H, membrane cofactor protein (MCP) or factor I. Mutations in factor B and C3 have also been reported recently. In addition, 10% of children have factor H dysfunction due to anti-factor H antibodies. Early age at onset appears as characteristic of factor H and factor I mutated patients, while MCP-associated HUS is not observed before age 1 year. Low C3 level may occur in patients with factor H and factor I mutation, while C3 level is generally normal in MCP-mutated patients. Normal plasma factor H and factor I levels do not preclude the presence of a mutation in these genes. The worst prognosis is for factor H-mutated patients, as 60% die or reach end-stage renal disease (ESRD) within the first year after onset of the disease. Patients with mutations in MCP have a relapsing course, but no patient has ever reached ESRD in the first year of the disease. Half of the patients with factor I mutations have a rapid evolution to ESRD, but half recover. Early intensive plasmatherapy appears to have a beneficial effect, except in MCP-mutated patients. There is a high risk of graft loss for HUS recurrence or thrombosis in all groups except the MCP-mutated group. Recent success of liver–kidney transplantation combined with plasmatherapy opens this option for patients with mutations of factors synthesized in the liver. New therapies such as factor H concentrate or complement inhibitors offer hope for the future.Keywords
This publication has 75 references indexed in Scilit:
- Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndromeBlood, 2008
- Translational Mini-Review Series on Complement Factor H: Renal diseases associated with complement factor H: novel insights from humans and animalsClinical and Experimental Immunology, 2008
- Translational Mini-Review Series on Complement Factor H: Therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritisClinical and Experimental Immunology, 2007
- Translational Mini-Review Series on Complement Factor H: Genetics and disease associations of human complement factor HClinical and Experimental Immunology, 2007
- Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domainsThe Journal of Experimental Medicine, 2007
- Deletion of Complement Factor H–Related Genes CFHR1 and CFHR3 Is Associated with Atypical Hemolytic Uremic SyndromePLoS Genetics, 2007
- Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndromeProceedings of the National Academy of Sciences, 2007
- Atypical Haemolytic Uraemic Syndrome Associated with a Hybrid Complement GenePLoS Medicine, 2006
- Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcomeBlood, 2006
- Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient miceProceedings of the National Academy of Sciences, 2006